MK-677 Calculator
MK-677 (also known as Ibutamoren) reconstitution and dosage reference — calculate vial concentration, BAC water volume, and exact syringe units below.
At the reference preset of a 60mg MK-677 vial reconstituted with 2 mL of bacteriostatic water, a 25mg dose measures 83.33 units on a U-100 insulin syringe.
MK-677 (ibutamoren) is an orally bioavailable, non-peptide growth hormone secretagogue.
- Concentration
- 30 mg/mL
- Draw volume
- 0.833 mL
- Units (U-100)
- 83.33
- Doses per vial
- ≈ 2
- Reference preset
- 60mg · 2mL · 25mg
Reference values from the default preset — adjust the calculator below for your vial.
What is MK-677?
MK-677 (ibutamoren) is an orally bioavailable, non-peptide growth hormone secretagogue. It mimics the action of ghrelin at the growth hormone secretagogue receptor (GHS-R), prompting the pituitary to release growth hormone in a pulsatile pattern and raising circulating IGF-1. Because it is a small molecule rather than a peptide, it is taken as a tablet or oral liquid and does not require reconstitution — any vial-and-syringe values shown here are illustrative only. MK-677 has been studied in clinical research for endpoints including growth hormone deficiency, age-related decline in GH, and muscle wasting, but it is not approved by the FDA for any indication and is handled as a research compound. Its long half-life means once-daily administration is typical in the research literature.
| 25 mg | lyophilized powder |
| 60 mg | lyophilized powder |
| 90 mg | lyophilized powder |
| 10 mg | ≈ 33.3 U-100 units (at 60mg / 2mL) |
| 15 mg | ≈ 50 U-100 units (at 60mg / 2mL) |
| 25 mg | ≈ 83.3 U-100 units (at 60mg / 2mL) |
How it's typically prepared
MK-677 is an orally active compound and does not typically require reconstitution. It is supplied either as capsules/tablets or as an oral solution measured by volume. The calculator on this page is included for consistency with the rest of the catalogue, but the reconstitution math does not apply to an oral product — read the supplier's stated concentration (for example, mg per mL of oral solution) to translate a target amount into a volume.
How MK-677 is described in research literature
Reference protocols in the research literature most commonly cite MK-677 in the 10–25 mg per day range, taken orally once daily, reflecting its long half-life. Because the compound is investigational and unapproved, there is no established clinical dose; these figures come from published trials and research reports rather than from a prescribing label. MK-677 raises growth hormone and IGF-1 without the injection and reconstitution steps that peptide secretagogues such as ipamorelin or sermorelin require, which is the main practical distinction researchers cite when comparing the two classes.
Unlike the GHRP and GHRH peptides on this site, MK-677 is not measured into an insulin syringe — an oral solution is dosed by volume against its stated concentration, and a tablet by its labelled milligram strength. Anyone cross-referencing MK-677 against injectable secretagogues should note that the receptor target (GHS-R, the ghrelin receptor) is shared with the GHRPs, but the route, half-life, and handling are entirely different.
MK-677 reported effects
The following effects are reported in the research literature and clinical trial records. This is an educational summary, not medical advice, and does not capture every possible effect.
- Increased appetite (consistent with ghrelin-receptor activity)
- Fluid retention and transient peripheral edema
- Lethargy or increased need for sleep in some reports
- Transient increases in fasting blood glucose and reduced insulin sensitivity
- Elevated IGF-1 above the reference range with sustained use
Frequently asked questions
- Is MK-677 a peptide?
- No — MK-677 is a non-peptide small molecule that mimics ghrelin's action at the growth hormone secretagogue receptor (GHS-R). It is grouped with growth hormone secretagogues by mechanism, not by structure.
- Does MK-677 need to be reconstituted?
- No. MK-677 is orally active and is supplied as tablets, capsules, or an oral solution. There is no powder to reconstitute and no injection involved.
- Is MK-677 FDA-approved?
- No. MK-677 (ibutamoren) has been studied in clinical trials but is not approved by the FDA for any indication. It is handled as a research compound.
- How is MK-677 described in research literature?
- Published research and trial records most commonly cite 10–25 mg taken orally once daily, reflecting the compound's long half-life. There is no established clinical dose because it is unapproved.
- How does MK-677 differ from injectable secretagogues like ipamorelin?
- MK-677 shares the ghrelin-receptor target with the GHRP peptides but is taken orally and has a much longer half-life, so it does not require the daily reconstitution and subcutaneous injection that peptides such as ipamorelin or sermorelin do.
PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.